GSA Capital Partners’s Milestone Pharmaceuticals MIST Stock Holding History

GSA Capital Partners’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32K	Sell	26,893 -209,245	-89%	-$366K	﹤0.01%	1627
2025 Q4	$477K	Buy	236,138 +157,391	+200%	+$339K	0.04%	842
2025 Q3	$157K	Buy	+78,747	New	+$138K	0.01%	1475
2023 Q4	–	Sell	-48,796	Closed	-$151K	–	1755
2023 Q3	$151K	Sell	48,796 -17,544	-26%	-$54.5K	0.01%	1339
2023 Q2	$189K	Sell	66,340 -33,428	-34%	-$126K	0.02%	1290
2023 Q1	$393K	Buy	+99,768	New	+$365K	0.04%	862

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

GSA Capital Partners's MIST Position: Q1 2026 in Review

GSA Capital Partners reduced its Milestone Pharmaceuticals (MIST) stake by 89% in Q1 2026, selling an estimated $366K and leaving 26,893 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

GSA Capital Partners first reported a position in MIST in Q1 2023 and has held it in 6 quarters since. The position peaked at $477K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

GSA Capital Partners held 26,893 shares of Milestone Pharmaceuticals worth $32K as of Q1 2026.
GSA Capital Partners sold 209,245 Milestone Pharmaceuticals shares in Q1 2026, an estimated $366K.
Milestone Pharmaceuticals made up ﹤0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1627 holding.
GSA Capital Partners first reported a position in Milestone Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
GSA Capital Partners's Milestone Pharmaceuticals position peaked at $477K in Q4 2025.
86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.